Inhibition of central nervous system axon growth is reportedly mediated in part by calcium-dependent phosphorylation of axonal epidermal growth factor receptor, with local administration of the epidermal growth factor receptor kinase inhibitors AG1478 and PD168393 to an optic nerve lesion site promoting adult retinal ganglion cell axon regeneration. Here, we show that epidermal growth factor receptor was neither constitutively expressed, nor activated in optic nerve axons in our nonregenerating and regenerating optic nerve injury models, a finding that is inconsistent with phosphorylated epidermal growth factor receptor-dependent intra-axonal signalling of central nervous system myelin-related axon growth inhibitory ligands. However, epidermal growth factor receptor was localized and activated within most glia in the retina and optic nerve postinjury, and thus an indirect glial-dependent mechanism for stimulated retinal ganglion cell axon growth by epidermal growth factor receptor inhibitors seemed plausible. Using primary retinal cultures with added central nervous system myelin extracts, we confirmed previous reports that AG1478/PD168393 blocks epidermal growth factor receptor activation and promotes disinhibited neurite outgrowth. Paradoxically, neurites did not grow in central nervous system myelin extract-containing cultures after short interfering ribonucleic acid-mediated knockdown of epidermal growth factor receptor. However, addition of AG1478 restored neurite outgrowth to short interfering ribonucleic acid-treated cultures, implying that epidermal growth factor receptor does not mediate AG1478-dependent effects. TrkA-/B-/C-Fc fusion proteins and the kinase blocker K252a abrogated the neuritogenic activity in these cultures, correlating with the presence of the neurotrophins brain derived neurotrophic factor, nerve growth factor and neurotrophin-3 in the supernatant and increased intracellular cyclic adenosine monophosphate activity. glial inhibitors. We attribute AG1478-stimulated neuritogenesis to the induced release of neurotrophins together with raised cyclic adenosine monophosphate levels in treated cultures, leading to axon growth and disinhibition by neurotrophin-induced regulated intramembraneous proteolysis of p75 NTR . These off-target effects of epidermal growth factor receptor kinase inhibition suggest a novel therapeutic approach for designing treatments to promote central nervous system axon regeneration.
Introduction
Epidermal growth factor receptor (EGFR) has multiple roles in the developing and mature central nervous system (CNS), mediating cell responses to mitotic stimuli that regulate neurogenesis (Blum, 1998) and gliogenesis (Rabchevsky et al., 1998) , and determining the cell fate of neural progenitor cells (Burrows et al., 1997; Lillien and Wancio, 1998; Lillien and Raphael, 2000; Neufeld, 2003, 2004) . During late ontogeny, EGFR activation regulates astrocyte development (Burrows et al., 1997) and EGFR ligands, such as transforming growth factor-and epidermal growth factor, provide neurotrophic signals for neurite outgrowth (Wildering et al., 2001) . After CNS trauma EGFR is rapidly up-regulated in astrocytes in response, for example, to ischaemia (Planas et al., 1998; Jin et al., 2002) , axotomy (Lisovoski et al., 1997) and glaucoma Neufeld, 2004, 2007; Liu et al., 2006; Erschbamer et al., 2007) . Conversely, the numbers of reactive astrocytes are reduced in EGFR À/À mice after cerebral lesions (Wagner et al., 2006) . The possible involvement of EGFR kinase activity in the mediation of axon growth inhibition and regeneration was suggested by the results of a high through-put technique designed to screen for small molecules which promote neurite outgrowth despite the presence of inhibitory agents (disinhibited growth) (Koprivica et al., 2005) . Of the 400 molecules tested, the reversible (AG1478) and irreversible (PD168 393) EGFR antagonists strongly promoted cerebellar granule, dorsal root ganglion neuron and retinal ganglion cell (RGC) neurite outgrowth on an immobilized CNS myelin inhibitory substrate. The in vivo application of AG1478 and PD168 393 to the lesion site of the transected mouse optic nerve promoted RGC axon regeneration through the wound and into the distal optic nerve segment (Koprivica et al., 2005) . More recently, it has been claimed that delivery of PD168 393 improves structural, locomotor, sensory and bladder recovery after spinal cord injury in rats (Erschbamer et al., 2007) . AG1478 also rescues RGC from death in a chronic glaucoma model, in which EGFR expression is restricted to astrocytes, suggesting that the beneficial effects of EGFR inhibition may be mediated primarily through astrocytes and not neurons Neufeld, 2004, 2007; Liu et al., 2006; Erschbamer et al., 2007) . EGFR ligands stimulate inhibitory chondroitin sulphate proteoglycan secretion (Smith and Strunz, 2005) and the formation of a cribriform astrocyte process lattice that may contribute to the formation of glial scars (Liu et al., 2002) , and from which additional inhibitory ligands emanate (Sandvig et al., 2004; Berry et al., 2008) .
EGFR kinase antagonists may act directly on neurons to attenuate inhibitory ligand signalling. For example, inhibitory ligands binding to NgR increase Ca 2+ influx, which transactivates EGFR, triggering the Rho/ROCK (Rho-associated, coiled-coil containing protein kinase) inhibitory signalling cascade through an unknown mechanism (Koprivica et al., 2005) . According to this model, EGFR blockade by AG1478/PD168393 promotes CNS neurite/axon regeneration solely by paralysis of the axon growth inhibitory signalling pathway. However, we and others have demonstrated that optimal conditions for regeneration of CNS neurites/axons in the presence of inhibitory ligands, require concomitant stimulation of axon growth and blockade of inhibitory signalling through regulated intramembraneous proteolysis, both of which are induced by neurotrophic factors (Ahmed et al., 2006b; Fischer et al., 2004a, b; Logan et al., 2006) . The initiation of regulated intramembraneous proteolysis by neurotrophic factors is a two stage degradation of p75 NTR in which an -secretase [e.g. tumour necrosis factor alpha converting enzyme (TACE)], cleaves the extracellular domain (p75 ECD ), initiating g-secretase shedding of the intracellular domain (p75 ICD ). RhoA is inactivated and protects axon growth cones from collapse by retarding actin depolymerisation (Logan et al., 2006; Ahmed et al., 2006a, b) .
Since axons blinded to CNS growth inhibitors by EGFR antagonistmediated disinhibition require an additional stimulus for driving growth through the inhibitory environment of the CNS (Ahmed et al., 2009a) , we hypothesized that EGFR inhibitors are likely to act off-target to drive RGC axon regeneration, possibly through the release of neurotrophic factors which induce both regulated intramembraneous proteolysis and axogenic protein synthesis in RGC axons and somata (Ahmed et al., 2006b; Logan et al., 2006) . On-target axogenic AG1478/PD168393 effects require the presence of phosphorylated (p) EGFR within axotomized RGC somata and their injured axons, a requisite that predicts lowered or absent pEGFR titres in RGC and their axons in our regenerating compared to non-regenerating optic nerve injury models (Berry et al., 1996) . We report our findings showing that to the contrary, off-target effects mediate AG1478/PD168393 axogenesis and that axogenesis/neuritogenesis is unrelated to EGFR kinase inactivation. Instead, the effect is mediated through off-target Trk activation by the neurotrophins nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3) and raised cyclic adenosine monophosphate (cAMP) levels found in AG1478+CME-conditioned medium from retinal cultures. Raised cAMP levels, together with the release of RGC/glia-derived neurotrophins, have the dual action of driving and also disinhibiting neurite outgrowth by the induction of regulated intramembraneous proteolysis of p75 NTR . These findings are relevant to multiple neural systems including, for example, dorsal root ganglion neurons (Ahmed et al., 2009b) .
Methods

In vivo experimental design
The experimental design comprised five groups each containing three adult (200-250 g), inbred Fischer F344 female rats (Charles River, Margate, UK) for each analytical end-point (n = 6 optic nerves and 6 retinae), designated as: (i) uninjured controls; (ii) sham intravitreal implantation without optic nerve crush (ONC) controls; (iii) nonregenerating models: (a) sham intravitreal implantation with ONC; and (b) ONC alone; and (iv) a regenerating model = ONC with intravitreal sciatic nerve implantation (Berry et al., 1996 (Berry et al., , 1999 . The relative levels and cellular localizations of pEGFR were monitored in all groups to evaluate: (i) baseline constitutive levels in the uninjured control group; (ii) the effects of intravitreal injury in sham intravitreal implantation with ONC rats on (a) retinal and optic nerve levels of pEGFR; and (b) RGC axon regeneration; (iii) the effects of intravitreal injury on retinal and optic nerve levels of pEGFR in sham intravitreal implantation without ONC animals; and (iv) comparisons of pEGFR levels in retina and optic nerve between non-regenerating and regenerating groups, providing data to correlate with the regenerative status of axons [confirmed by growth associated protein (GAP)-43 staining in optic nerve sections], and the reaction of glia to optic nerve crush. Each group comprised three independently repeated experiments.
Surgical procedures
All surgical procedures were licensed by the UK Home Office, approved by the local ethics committee and conducted under inhalation anaesthesia induced with 5% isofluorane with 1.5 l/min O 2 and maintained with reducing levels of isofluorane. In the nonregenerating and regenerating model groups, exposed optic nerves were crushed intra-orbitally after a lepto-meningeal incision to avoid damage to the central retinal artery. Complete transection of RGC axons was confirmed visually by physical separation of the cut nerve endings within the pial sheath. Regenerating group animals had a teased 2 mm long segment of sciatic nerve, obtained from the same strain of rat, grafted into the vitreous body through a scleral incision and retained with a piece of Sterispon sponge (Johnson and Johnson, NJ, USA) plug immediately after ONC. After 14 days all rats were killed by CO 2 narcosis.
Antibodies
The characteristics of all antibodies used in this study are detailed in Table 1 .
Immunohistochemistry and immunocytochemistry
(i) For pEGFR immunohistochemistry, the optic nerve and eyes from adult Fischer rats were fixed by intracardiac perfusion with 4% paraformaldehyde in phosphate buffered saline (PBS). The optic nerves and eyes were cryoprotected through graded concentrations of sucrose solutions (10%-30%) before embedding in optic nerve crush mounting medium (Raymond Lamb, Peterborough, UK), and freezing on dry ice for storage at À80 C. Longitudinal optic nerve and para-sagittal eye sections were cut at a thickness of 15 mm using a Bright 5030 Cryostat (Bright Instruments, Cambridgeshire, UK), mounted onto charged slides (Surgipath, Peterborough, UK), and stored at À20 C. Sections were fixed in 100% ethanol for 1 min, washed twice for 5 min in Tris buffered saline (TBS), followed by a 10 min immersion in TBS plus 0.1% Triton-X-100 (Sigma). After the application of blocking solution/antibody diluting buffer-(1% bovine serum albumin) (BSA, Sigma), 0.5% Tween 20 (Sigma), 5% non-immune serum (Vector Labs, Peterborough, UK) in PBS, sections were incubated in an enclosed humidified chamber overnight ($16 h) at 4 C in antibody diluting buffer containing the relevant primary antibody dilution (Table 1) . After three 10 min TBS washes, sections were incubated with secondary antibody solutions (Table 1) for 60 min at room temperature, washed three times for 5 min in PBS, drained, mounted with Vectamount containing DAPI (Vector Labs), and stored at 4 C before examination using a Zeiss Axioplan 2 fluorescence microscope (Carl Zeiss, Hertfordshire, UK). Western blots of protein extracts of lesioned optic nerve confirmed pEGFR antibody detection of a predicted single band of 170 kDa ( Supplementary Fig. 1A , Lane 1). Antibody specificity was verified by pre-incubating the primary antibody with excess immunogenic peptide (Santa Cruz, CA, USA) at a peptide:antibody ratio of 20:1 ( Supplementary  Fig. 1A , Lane 2). In retinal/optic nerve sections, all pEGFR immuno-staining was blocked with antibody pre-absorption at a 20:1 immunizing peptide:antibody ratio (e.g. Supplementary  Fig. 1B and C). (ii) In vivo neurotrophin expression in retinae after PD168393 treatment was monitored by immunohistochemistry in retinal sections from adult rats Wistar rats (200-250 g) with optic nerve crush (see above). Three optic nerve crush rats received 10 ml of 10 mM PD168393 and three optic nerve crush controls received 10 ml PBS intravitreally, without injuring the lens at 0, 4, 8 and 11 days. All were killed at 14 days. Parasagittal retinal sections, 15 mm thick, were mounted onto charged slides and exposed with NGF, BDNF, and NT-3 primary antibodies (Table 1) . Only NT-3 immunohistochemistry is presented (see Supplementary Fig. 7 ) since only a weak signal for NGF and BDNF in the ganglion cell layer was obtained. (iii) Sustained regeneration of axons in the regenerating model and abortive regeneration in the non-regenerating model groups of adult Fischer rats at 20 days after optic nerve crush, was monitored using GAP-43 immunohistochemistry. Frozen 15 mm thick longitudinal sections of optic nerve were brought up to room temperature, washed for 5 min in TBS, left standing in 100% methanol (Sigma) for 10 min and then incubated for 1 h in a blocking solution of 10% normal donkey serum in TBS. Sections were then incubated overnight at 4 C in a humidified chamber in 1:1250 dilution of primary GAP-43 antibody (Table 1) in antibody diluting buffer [5% normal donkey serum, 2% BSA in TBS2T (TBS, 0.3M NaCl)], and then washed in TBS2T for 1 h, followed by two 1 h washes in antibody diluting buffer and TBS2T. Sections were incubated in 1:500 dilution of secondary antibody ( 
Confocal microscopy
Sections of optic nerve and retina were processed for pEGFR immunohistochemistry, as described above, and visualized on a Zeiss LSM 510 confocal microscope.
Adult retinal cultures
Retinal samples from adult rats (200-250 g) were dissociated into single cells using a papain dissociation kit using the manufacturer's instructions (Worthington Biochem, New Jersey, USA) for 2 h at 37 C in a humidified atmosphere containing 5% CO 2 , pelleted and then resuspended in Neurobasal-A containing B27 supplement, chamber slides (BD Biosciences, Oxford, UK) pre-coated with 100 mg/ml poly-D-lysine followed by 20 mg/ml Laminin-I (Sigma, Dorset, UK) in four-well tissue culture plates (Nunc, UK). Cells were grown in supplemented Neurobasal-A medium, in the presence of rat central nervous system myelin extracts (CME) which contains all CNS myelin inhibitors (Ahmed et al., 2005 (Ahmed et al., , 2006b Logan et al., 2006) for 72 h at 37 C in a humidified atmosphere containing 5% CO 2 .
To determine whether the indirect effects of AG1478 is induced by the production of soluble factors into the culture medium, mixed retinal cells with added CME were stimulated with a 5 h pulse of AG1478, after which all traces of AG1478 were removed by washing three times in sterile PBS. Fresh culture medium was added to the cells which were grown for a further 3 days to condition the medium. Conditioned medium was then collected and applied to freshly isolated retinal cells at a 1:10 dilution in the presence of CME. Cells were then immunostained with bIII-tubulin antibodies and RGC neurite outgrowth was quantified. Conditioned medium was also collected from retinal cultures not exposed to AG1478 and included as a control. The kinase inhibitor K252a (Nye et al., 1992; Tapley et al., 1992; Morotti et al., 2002 ) was used at a final pre-determined concentration of 50 nM to block RGC neurite outgrowth (Lorber et al., 2002 ) (see Supplementary Fig. 6 ).
To limit non-neuronal cell proliferation, the mixed retinal cultures were treated with 30 mM 5-fluoro-2-deoxyuridine (5-FDU, Sigma) daily throughout the culture period (Ahmed et al., 2006a) .
Measurement of bIII-tubulin+ neurite outgrowth
Photomicrographs of bIII-tubulin + immunostained RGC neurites were captured using Axiovision Software (Carl Zeiss) from 30 randomly selected RGC/coverslip and measured using the built-in facilities in Axiovision. A total of 270 RGC were analysed for each condition and each experiment was performed in triplicate on three separate occasions. RGC neurite lengths and numbers of RGC with neurites were represented as mean AE SEM.
Counting of RGC and non-neuronal cells
The numbers of RGC and non-neuronal cells present in the mixed retinal cultures were determined after double staining cultures with bIII-tubulin (to identify RGC) (Ahmed et al., 2006b; Suggate et al., 2009) and DAPI (to identify all cell nuclei) (Ahmed et al., 2006a) . Chambers (n = 3/condition, three independent experiments) were partitioned into nine equal quadrants and, in each, random photomicrographs of merged images from bIII-tubulin/DAPI stained retinal cultures were captured using Axiovision Software (Carl Zeiss) and the relative number of bIII-tubulin + RGC and DAPI stained cells estimated.
Short interfering ribonucleic acid preparation and transfection
A short interfering ribonucleic acid (siRNA) sequence directed against EGFR (siEGFR, sense 5 0 -GAAGAGACCUGCAUUAUCAUU-3 0 ) was purchased from Dharmacon (Colorado, USA) and used to knockdown EGFR mRNA, reducing EGFR protein by 490%. Lipofectamine 2000 reagent (Invitrogen) was used to transfect RGC with 50 nM siEGFR following the manufacturer's instructions. RGC were also transfected with Lipofectamine alone (sham), a scrambled version of the above siEGFR sequence (Dharmacon) and siRNA targeting green fluorescent protein (Dharmacon) as controls. After 5 h of transfection, supplemented Neurobasal-A was added to the transfection medium to bring the final volume to 500 ml/chamber and RGC were incubated for a further 48 h either in the presence or absence of either CME, or AG1478 before cell lysis and immunocytochemistry. Each experiment was performed in triplicate and repeated on three separate occasions.
Protein extraction and Western blotting
For determination of pEGFR levels in the optic nerve, tissues from three rats (n = 6) per treatment group were washed twice with PBS, homogenized in ice-cold lysis buffer (20 mM Tris-HCl at pH 7.4, 1 mM ethylene diamine tetraacetic acid (EDTA), 0.5 mM ethylene glycol tetraacetic acid (EGTA), 150 mM NaCl, 1% NP-40 and a protease inhibitor cocktail) (all from Sigma), and incubated at 4 C with constant agitation. Lysates were then clarified by centrifugation at 13 000 rpm for 30 min at 4 C and normalized for protein concentration using a colorimetric DC protein assay (Bio-Rad, Hercules, CA, USA). Supernatants were stored at À80 C.
To determine levels of TACE, p75 NTR , p75 ECD , p75 ICD and RhoA in treated retinal cultures, cells were washed twice with PBS and incubated in ice-cold lysis buffer containing 20 mM Tris-HCl (pH 7.4), 1 mM EDTA, 0.5 mM EGTA, 150 mM NaCl, 1% NP-40 (Sigma) and a protease inhibitor cocktail (Sigma), incubated at 4 C with constant agitation and left on ice for a further 30 min. Lysates were then clarified by centrifugation at 13 000 rpm for 30 min at 4 C and normalized for protein concentration using a colorimetric DC protein assay (Bio-Rad, Hercules, CA, USA). Supernatants were stored at À80 C.
For Western blot analysis, each 20 mg total protein sample was incubated with Laemmeli loading buffer at 90 C for 4 min and separated on a 10% sodium dodecyl sulfate-polyacrylamide gel (Invitrogen). Proteins were transferred to polyvinylidene fluoride membranes (Millipore UK, Gloucestershire, UK), blocked for 1 h at room temperature in TBS containing 0.1% Tween 20 and 5% non-fat milk. Membranes were blotted overnight with the appropriate primary antibody (Table 1) , diluted in non-fat milk. Enhanced chemiluminescence (Lehmann et al., 1999) (Amersham, Buckinghamshire, UK) and horseradish peroxidase (HRP)-conjugated secondary antibody (1:1000, Amersham, Table 1) were used for detection. Each blot was stripped in 10 mM glycine buffer (pH 2.0) and re-probed with appropriate antibodies (Table 1) including b-actin (Sigma), which acted as a loading control.
Densitometry
Western blots were scanned into Adobe Photoshop CS3 (Adobe Systems, San Jose, CA, USA), keeping all scanning parameters the same and the TIFF files were analysed by densitometry in ScionImage (Scion Corp, MD, USA), using the built-in gel plotting macros. The integrated density of each band was calculated from at least three independent experiments for each protein analysed.
Size fractionation of conditioned medium
Conditioned media from AG1478 exposed retinal cultures were collected, briefly centrifuged at 13 000 Â rpm for 5 min to remove cell debris, followed by size fractionation using commercially available ultrafiltration spin columns (Millipore, Watford, UK), according to the manufacturer's instructions. Three samples were collected which contained protein sizes: (i) 4100 000 kDa; (ii) 10 000-100 000 kDa; and (iii) 510 000 kDa fractions, and the bioactivity of each fraction compared with unfractionated conditioned medium after application of an equal volume of conditioned medium onto freshly isolated CME-inhibited retinal cultures.
Affinity/ion exchange chromatography
An SP-Sepharose column (GE Healthcare, Buckinghamshire, UK) was equilibrated with 10 column volumes of 50 mM Tris buffer at pH 7.4. Fractionated conditioned media were loaded onto the column and the flow though collected. The column was then washed with three column volumes of 50 mM Tris buffer. Bound proteins were then eluted with increasing concentrations of NaCl ranging from 100, 250, 500 mM to 1 M. Fractions from each elution fraction were collected and their axogenic potency tested in retinal culture assays to determine the active fraction, as described in the previous section.
Treatment of cultures with Trk-Fc fusion proteins
In affinity purified conditioned medium from AG1478-treated retinal cultures, TrkA, TrkA-B and TrkA-C-Fc fusion proteins were used to block the neuritogenic activity in retinal cultures. The three Trk-Fc fusion proteins were used individually or in combination, at a concentration of 5 mg/ml each (1-2 mg/ml commonly used in previous reports, e.g. Hartmann et al., 2004; Tanaka et al., 2008) .
Neurotrophin ELISA
The levels of NGF, BDNF and NT-3 in the conditioned medium from AG1478-treated retinal cultures were assayed by ELISA using E max Immunoassay Kits (Promega) that can detect down to 10 pg/ml of the relevant neurotrophin, following the manufacturer's instructions. Briefly, after constructing a standard curve ranging from 300 to 4.7 pg/ml, several dilutions of the test sample was assayed in duplicate for each neurotrophin using the relevant kit. Regression analysis was then performed on standards and sample concentrations were determined with reference to the linear portion of the standard curve.
Rho activation assay
GTP-bound Rho was assayed from tissue and cell lysates using a Rho activation assay kit (Upstate Biotechnology, Milton Keynes, UK) following the manufacturer's instructions and as described previously (Ahmed et al., 2006a, b; Logan et al., 2006) .
Statistical analysis
Unless otherwise stated, each experiment was performed in triplicate and repeated on three separate occasions. Sample means were calculated and analysed for significance using GraphPad Prism (GraphPad Software Inc., Version 4.0, San Diego, USA) by one-way analysis of variance (ANOVA) followed by post hoc testing with Dunnett's method to identify statistically significant groups.
Results
RGC axons regenerated in regenerating but not in non-regenerating optic nerve
No differences were detected in the regenerative potential and activation of EGFR between optic nerve crush alone and sham intravitreal implantation with optic nerve crush groups and thus both groups are designated non-regenerating groups hereafter. As already demonstrated in the regenerating group at 20 dpl, RGC axons regenerate through the lesion and into the distal optic nerve, chiasm and optic tract (Berry et al., 1996 (Berry et al., , 1999 . At 14 dpl, GAP-43 staining of optic nerve sections revealed the aborted axonal regeneration that occurred in the transected optic nerve of the non-regenerating groups (Supplementary Fig. 2A ), and axon growth through the lesion site and into the distal optic nerve segment of regenerating group rats after intravitreal sciatic nerve implantation at the time of optic nerve crush ( Supplementary Fig. 2B ).
Cellular localization of pEGFR
Although EGFR mRNA is constitutively expressed in RGC in vivo and in vitro (Koprivica et al., 2005) , EGFR was neither constitutively activated, nor activated in most RGC somata and their optic nerve axons after optic nerve crush in either the non-regenerating groups (where EGFR activation in RGC and their axons was expected to be maximal), or regenerating group (where EGFR activation in RGC and their axons was expected to be minimal) (Fig. 1A-D , Table 2 ), although RGC were always strongly pEGFR + in culture ( Fig. 1E and Supplementary Fig. 3 ). Like other studies in the injured CNS , pEGFR was constitutively localized in vivo in retinal astrocytes and Mü ller cells ( Supplementary Fig. 4 ) and optic nerve glia including optic nerve astrocytes (Fig. 1C) and oligodendrocytes ( Fig. 1D ) and, although glial pEGFR levels were enhanced 14 days after optic nerve crush (sham intravitreal implantation with and without ONC groups, and regenerating group) ( Supplementary Fig. 4) , there was no difference in expression of non-activated EGFR in the nonregenerating and regenerating groups, although glial fibrillarry acidic protein (GFA)P + astrocytes and Mü ller cells became reactive in all groups after vitreal trauma (sham intravitreal implantation with and without ONC groups; and regenerating) ( Supplementary  Fig. 4 ). AG1478 blocked EGFR activation and disinhibited RGC neurite outgrowth in the presence of inhibitory CME.
The addition of CME to retinal cultures enhanced the levels of pEGFR by 40% compared to untreated control cultures while the addition of AG1478 suppressed pEGFR levels by more than 70% compared to controls (Fig. 2A) . Ciliary neurotrophic factor (CNTF)-mediated neurite outgrowth observed in control retinal cultures (Fig. 2B) was blocked by the addition of CME, confirming the efficacy of our inhibitory culture conditions (Fig. 2C) . In contrast, in cultures with added AG1478, RGC neurite outgrowth was not inhibited by the addition of CME (Fig. 2D) . For example, the frequency of both RGC with neurites and mean length of neurites was significantly enhanced (P50.0001) compared with CNTF control levels ( Fig. 2E and  F) . PD168393 also promoted an increase in the number of RGC with neurites similar to that seen after AG1478 treatment, although mean neurite length was significantly longer (Supplementary Fig. 5 ).
AG1478 promoted RGC neuritogenesis despite over 90% knockdown of EGFR Our siEGFR sequence achieved a mean 90% knockdown of EGFR protein in retinal cultures with added CME (Fig. 3A and B) . Surprisingly, this level of siRNA knockdown of EGFR did not promote RGC neurite outgrowth in the presence of CME whereas, addition of AG1478 to siEGFR-treated retinal cultures containing CME, stimulated RGC neurite outgrowth to levels similar to those seen after AG1478+CME/-siEGFR treatment (compare Fig. 2D and E with Fig. 3C and D) , demonstrating that EGFR antagonism is redundant and that AG1478 releases a trophic stimulus into the medium through an off-target mechanism.
Trk receptor activation mediated off-target AG1478-induced neuritogenesis
The basal level of RGC neurite outgrowth seen in retinal cultures (Fig. 4A , G and H) was enhanced by CNTF (Fig. 4B , G and H), but completely suppressed after the addition of CME (Fig. 4C , G and H). Addition of AG1478 to retinal cultures containing CME stimulated RGC neurite outgrowth (Fig. 4D , G and H) above control CNTF levels. The gp130 component of the CNTF receptor was blocked with MAb228 (Lorber et al., 2002) (Fig. 4E , G and H), and Trk-dependent neurotrophin signalling was blocked by the addition of the kinase inhibitor K252a (Fig. 4F , G and H). The former agent had no effect on RGC neurite outgrowth, excluding a role for CNTF, but the latter suppressed AG1478-stimulated RGC neurite outgrowth in the presence of CME ( Fig. 4H and G) and in a dose dependent manner ( Supplementary Fig. 6 ), implicating Trk-dependent processes and a potential requirement for Trk-dependent neurotrophins to drive disinhibited RGC neurite outgrowth in the presence of CME.
Figure 2 EGFR inhibitors block EGFR phosphorylation and enhance RGC neurite outgrowth in retinal cultures. (A) Western blot and
densitometry data presented as a graph to show that EGFR inhibitors suppress EGFR activation. RGC neurite outgrowth in retinal cultures: (B) with CNTF but no CME; (C) with CNTF+CME, in which RGC neurite outgrowth was inhibited; (D) AG1478 + CME, in which RGC neurite outgrowth was disinhibited. Quantification to show that AG1478 increased: (E) RGC survival; and (F) RGC neurite length. Scale bar = 40 mm, ***P50.0001. Inhibiting glial proliferation attenuated AG1478-stimulated RGC neurite outgrowth
EGFR antagonists promote neurite outgrowth
Since our cultures are comprised of a mixture of retinal neurons and glia (Suggate et al., 2009) , the possibility that glia influenced AG1478-stimulated RGC neurite outgrowth was assessed by blocking glial proliferation using 5-fluoro-2-deoxyuridine (5-FDU) (Ahmed et al., 2005 (Ahmed et al., , 2006a . The number of glia in 5-FDUtreated cultures was reduced by half of that observed in the presence of 5-FDU + CME and 5-FDU + AG1478 (Fig. 5A) . However, 25% more RGC survived in cultures treated with AG1478 + 5-FDU+CME (Fig. 5B) , confirming the neuroprotective effects of AG1478 + CME (Fig. 2D ). Reducing glia numbers by half decreased the number of AG1478-stimulated RGC with neurites and the mean neurite length by 50% (compare Fig. 2 with Fig. 5C and D, respectively). For example, the number of RGC with neurites after treatment with AG1478 ( Fig. 2D) , in which retinal cells are not exposed to 5-FDU, is 120 AE 8 compared to 60 AE 5 RGC in the presence of 5-FDU (Fig. 5C ). As for RGC neurite length in the absence of 5-FDU (Fig. 2E) , it was 180 AE 20 mm and 90 AE 10 mm in the presence of 5-FDU (Fig. 5D ). These results suggest that although RGC express and activate EGFR, EGFR + glia play an important role in the promotion of AG1478-stimulated neurite outgrowth.
AG1478-treated retinal culture medium contained soluble RGC neuritogenic factors
As predicted, few neurites grew from RGC in freshly isolated retinal cultures with added CME after a 3 day exposure to a 1:10 dilution of the conditioned medium from control plus CME, and control plus K252a plus CME cultures (e.g. Fig. 6A, D and E) . However, after exposure to AG1478-treated conditioned medium in retinal cultures with added CME, similar numbers of RGC grew neurites with similar mean lengths (Fig. 6B, D and E) to those seen after primary exposure to AG1478 (compare Fig. 6D and E, with
Figs. 2D, E and 4G, H). As before, addition of K252a to retinal cultures at the same time as AG1478 conditioning completely abrogated RGC neurite outgrowth seen after application of AG1478-conditioned medium alone ( Fig. 6C-E) . The AG1478-conditioned medium that did, and the control medium that did not stimulate RGC neurite outgrowth were size fractionated. No active fractions were detected in either the latter or the 510 and 4100 kDa fractions of the former (Fig. 7C and D) , but the 10-100 kDa fraction of the former was neuritogenic (Fig. 7A, C and D) and of similar potency to the unfractionated AG1478-conditioned medium (Fig. 7B, C and D) . RGC survival was unaffected by exposure to all fractions (Fig. 7E) . The 100-250 mM salt eluate of the 10-100 kDa conditioned medium fraction stimulated similar numbers of RGC to produce neurites (Fig. 8A ) of similar length (Fig. 8B) to those observed in control AG1478-conditoned retinal cultures.
Trk-Fc fusion proteins attenuated AG1478-stimulated RGC neurite outgrowth
The application of Trk-Fc fusion proteins (TrkA, B and C) either individually, or in combination with the 100-250 mM salt eluate from the 10-100 kDa active fraction of AG1478-treated retinal culture medium, attenuated the number of RGC with neurites (Fig. 8C) . The mean neurite length (Fig. 8D) , with the combined Trk-Fc fusion proteins to TrkA + TrkB + TrkC, almost completely ablated disinhibited RGC neurite outgrowth. These results suggest that the growth promoting activity of AG1478 may be through the activation of Trk-dependent neurotrophins such as NGF, BDNF and NT-3/4.
RGC and glia expressed neurotrophins in AG1478-treated retinal cultures and in PD168393-treated retinae in vivo
We used commercially available ELISA kits to determine the relative proportions of Trk-dependent neurotrophins in AG1478-treated retinal culture conditioned medium, and demonstrated that high titres of NGF, BDNF, and NT-3 were present (Fig. 9A) . We also confirmed, by immunocytochemistry, that both RGC and non-neuronal retinal cells were the source of these neurotrophins in AG1478-treated retinal cultures (Fig. 9B-D) .
In an in vivo paradigm, intravitreal injection of the irreversible EGFR inhibitor PD168393, rather than AG1478, was used to minimize the number of injections throughout a 15 day time period and assess if a similar induction of neurotrophins could be elicited from RGC and retinal glia. Using NT-3 immunohistochemistry as an indicator of the effect of EGFR inhibitors, PBS injections did not enhance levels of NT-3 immunolocalization in the retina (Supplementary Fig. 7A ). However, injection of PD168 393 enhanced the levels and immunolocalization of NT-3 in cells of the ganglion cell layer, including morphologically identified RGC somata. (Supplementary Fig. 7A and B) . (A) Little neurite outgrowth occurred in cultures without CME; (B) CNTF with no CME enhanced neurite outgrowth; (C) CME inhibited neurite outgrowth; (D) CME and AG1478 disinhibited neurite outgrowth; (E) MAb228 did not block AG1478 plus CME disinhibited neurite outgrowth; and (F) K252a almost ablated all AG1478 plus CME disinhibited neurite outgrowth. Quantification showing that AG1478 enhanced the mean number of RGC with neurites (G) and neurite length (H). Scale bar in (A)-(F) = 40 mm. *P50.05, **P50.001, ***P50.0001. Brain 2009: 132; 3102-3121 | 3111 Components of the regulated intramembraneous proteolysis cascade are modulated in retinal cultures exposed to AG1478 conditioned medium Neurotrophic factors induce TACE activation leading to regulated intramembraneous proteolysis of p75 NTR (Ahmed et al., 2006a, b; Logan et al., 2006) , and in AG1478-treated cultures, in which levels NGF, BDNF and NT-3 are raised. TACE levels were increased and full length p75 NTR was cleaved to a greater extent than in control and AG1478 + K252a cultures. For example, in AG1478-treated retinal cultures, levels of p75 ECD in the supernatant and p25 ICD in cell lysates were raised with concomitant reduction in full length p75 NTR and Rho-GTP (Fig. 10) . Addition of K252a in the presence of AG1478 almost completely inhibited TACE activation, maintaining control levels of full length p75 NTR and
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Rho-GTP with little change in p75 ECD in the medium and p25 ICD in the lysate (Fig. 10) , indicating that regulated intramembraneous proteolysis was neurotrophin-induced and independent of EGFR activation.
AG1478 treatment raised cAMP levels and addition of neurotrophins in combination with raised cAMP levels mimicked RGC neurite outgrowth promoted by AG1478
We then investigated the possibility that cAMP levels may also be raised after treatment of retinal cultures with AG1478, and correlated with the robust neurite outgrowth response. With AG1478, levels of cAMP were 450% than those detected in control cultures with and without added CME (Fig. 11A, P50 .0001), demonstrating that an additional off-target effect of AG1478 in retinal cultures is the elevation of cAMP levels. We then performed experiments in CME-inhibited retinal cultures to determine if addition of the equivalent concentrations of NGF, BDNF and NT-3 found in AG1478-conditioned medium disinhibited RGC neurite outgrowth to the levels seen in AG1478-treated cultures. Addition of NGF, BDNF and NT-3 singly showed that only BDNF promoted limited disinhibited RGC neurite outgrowth (Fig. 11B, C and D) while addition of all three neurotrophins in combination modestly enhanced RGC neurite outgrowth (Fig. 11B, C and D) . However, addition of forskolin to raise cAMP levels in combination with the triple neurotrophin combination significantly disinhibited RGC neurite outgrowth compared to triple neurotrophin without forskolin treatment (P50.0001), resembling the levels of neurite outgrowth observed with AG1478 alone (compare Fig. 11B and D with Fig. 2C-E) . Thus, combinations of neurotrophins together with raised cAMP levels are required for optimal disinhibited RGC neurite outgrowth and mimic the effects of AG1478.
Discussion
We have replicated the findings of Koprivica et al. (2005) , showing that EGFR kinase inhibitors (AG1478/PD168 393) inactivate EGFR and promote disinhibited RGC neurite growth in primary retinal cultures containing CME. However, we attribute this finding not to inactivation of axonal EGFR, but to off-target effects on RGC/retinal glia through the induced secretion of neurotrophins which both promote disinhibited RGC neurite outgrowth after blinding their growth cones to CME, and induce regulated intramembraneous proteolysis of p75 NTR . This conclusion is supported by our findings that: (i) in vivo, in both the regenerating and non-regenerating models, pEGFR was localized in retinal and optic nerve glia and found in occasional RGC somata but absent from their optic nerve axons and growth cones; (ii) blocking EGFR translation with siEGFR did not mimic the effects of either AG1478 or PD168393; (iii) AG1478 Figure 6 The neurites of RGC in retinal cultures exposed to AG1478-conditioned medium promoted neurite outgrowth. (A) No RGC neurite outgrowth was observed in conditioned medium from control cells cultured without AG1478 or K252a. (B) Significant neurite outgrowth was promoted by AG1478-conditioned medium. (C) AG1478 + K252a-conditioned medium did not promote RGC neurite outgrowth. Quantification showing that only AG1478-conditioned medium from retinal cells increased mean number of RGC with (D) neurites and (E) neurite length. Scale bar in (A)-(C) = 20 mm.
neuritogenic potency was preserved after siRNA knock-down of the EGFR substrate; (iv) the kinase blocker K252a suppressed AG1478-stimulated RGC neuritogenesis; (v) the supernatant of AG1478-treated retinal cultures contained soluble neuritogenic factor(s) blocked by K252a; (vi) the supernatant of AG1478-treated retinal cultures contained NGF, BDNF and NT-3, the latter at the highest concentration, with the addition of TrkA, B, and C Fc fusion proteins greatly attenuating RGC neuritogenesis; (vii) glia numbers in retinal cultures correlated with the potency of AG1478-induced neuritogenesis, and NGF, BDNF and NT-3 proteins were expressed in astrocytes, Mü ller cells and RGC in AG1478-treated retinal cultures and PD168393-treated retinae in vivo; (viii) neurotrophins released from retinal glia/RGC after AG1478 treatment activated TACE and induced regulated intramembraneous proteolysis of p75 NTF ; and (ix) the neuritogenic effects of EGFR inhibitors mimic those seen after treatment with a combination of neurotrophins and raised cAMP levels.
EGFR is not activated in RGC somata or their optic nerve axons in either regenerating or non-regenerating groups Suppression of intra-axonal inhibitory signalling may be one explanation of how AG1478/PD168393-mediated EGFR blockade Figure 7 The 10-100 kDa fraction of AG1478-conditioned medium promoted significant disinhibited RGC neurite outgrowth in the presence of CME. (A) Normal RGC neurite outgrowth was observed in unfractionated AG1478-conditioned medium. (B) In fractionated AG1478-condtioned medium, RGC neurite outgrowth was only promoted by the 10-100 kDa fraction. Quantification showing that only the 10-100 kDa fraction increased the number of RGC with (C) neurites and (D) the mean neurite length, but (E) RGC survival was not significantly different in any of the treatments. Scale bar in (A) and (B) = 20 mm.
promotes CNS axon regeneration (Koprivica et al., 2005) . However, since pEGFR immunoreactivity was exclusively found in retinal and optic nerve glia and occasional RGC somata, but was absent from their axons and growth cones in regenerating and non-regenerating models, our results demonstrate that pEGFR cannot directly regulate intra-axonal inhibitory ligand signalling in the injured optic nerve, but are consistent with EGFR inhibitors having either (i) off-target intra-RGC axonal/ somata actions; and/or (ii) glial on-target or off-target effects (discussed later) that modulate both RGC inhibitory signalling and axon growth stimulation. Like other studies in the injured CNS (Liu and Neufeld, 2003 , 2004 , 2007 Liu et al., 2006) , we also found that pEGFR was constitutively localized within rows of optic nerve glia, including astrocytes and oligodendrocytes (and probably also synantocytes) Berry et al., 2002) , strengthening our assertion that EGFR inhibitors may have glial-derived effects that contribute to RGC axon regeneration. In contrast, most RGC somata and their neurites in vitro were positive for pEGFR. It is likely that EGFR activation in RGC during the retinal culture dissociation protocol and therefore the in vitro data must carry the caveat that it may not exactly reflect the in vivo paradigm. Nonetheless, EGFR inhibitors applied in vitro and in vivo stimulate neurotrophin production similarly and glia are EGFR + in both.
EGFR titres obtained by Western blotting of proteins from retinal culture lysates exposed to siEGFR are estimates of EGFR knockdown against a background of residual recycling EGFR translated before exposure to siEGFR. Levels of EGFR remaining in siEGFR-treated cultures were 510% of those in control untreated cultures, amounts that are unlikely to sustain EGFR-mediated axogenic inhibition. Thus, both siEGFR and AG1478 would be expected to be neuritogenic, and accordingly RGC neurite growth will not be stimulated by AG1478 in siEGFR-treated retinal cultures. However, siEGFR did not promote RGC neurite outgrowth in retinal cultures with added CME, and the combination of CME+AG1478 was as neuritogenic in cultures with and without added siEGFR, indicating that EGFR may be irrelevant to the neuritogenic potency of AG1478. Moreover, since siEGFR knocks down EGFR in both neurons and glia, AG1478 effects are off-target in both cellular phenotypes.
AG1478/PD168393 stimulate the release of NGF, BDNF and NT-3, and raises cAMP levels in retinal cultures
In our retinal cultures with added CME, RGC survival was increased after AG1478 treatment by 20%. This level of survival was maintained after AG1478 plus siEGFR treatment. It is well established that Trk-dependent neurotrophins regulate RGC survival in vitro and in vivo (Hu et al., 2005; Leaver et al., 2006; Harvey et al., 2006 Harvey et al., , 2007 by binding Trk and/or low affinity p75 NTR (Huang and Reichardt, 2003; Barker, 2004; Urra et al., 2007) . Neurotrophins promote neuronal survival by activating the PI3K/Akt intracellular cascade after Trk activation (Roux and Barker, 2002; Chao et al., 2006) , and similarly AG1478 may preserve the survival of RGC in a glaucoma model through neurotrophin-induced survival signalling (Liu and Neufeld, 2003; Liu et al., 2006) . RGC neurite/axon outgrowth is also stimulated through Trk and/or the low affinity neurotrophin receptor p75 NTR (Huang and Reichardt, 2003; Barker, 2004; Urra et al., 2007) , but requires activation of the RAS/extracellular signal kinase (ERK)/microtubule-associated protein kinase (MAPK) intracellular signalling pathway (Roux and Barker, 2002) . cAMP elevation by AG1478 has the potential to raise RGC survival and axon growth in response to neurotrophic factors (Cui et al., 2003; Rodger et al., 2005; Hu et al., 2007) and block CME-mediated inhibition (Cai et al., 1999) , all of which are dependent on the initial activation of the cAMP pathway executor protein kinase A, and subsequent multiple down-stream intracellular signalling pathways (Park et al., 2004) . ERK is activated in neurons by neurotrophins, inhibiting phosphodiesterase 4 thereby elevating cAMP (Cai et al., 1999) . cAMP reduces suppression of cytokine signalling expression, potentiating cytokine-induced axon growth (Park et al., 2009 ) and promotes axon/neurite growth over inhibitory myelin-associated glycoprotein and CME substrates, by suppressing axon growth inhibitory ligand signalling through either transcriptional up-regulation of arginase I and polyamines (Gao et al., 2004) , or neurotrophin-induction of regulated intramembraneous proteolysis of p75 NTF (Ahmed et al., 2005 (Ahmed et al., , 2006a Logan et al., 2006) . The observations that the medium from AG1478-treated retinal cultures contained physiological levels of NGF, BDNF and NT-3, that RGC survival and neurite outgrowth were blocked by K252a and Trk-Fc fusion proteins, and suppressed by reducing glial numbers, all support the hypothesis that AG1478 stimulated RGC/glia to release neurotrophin (as discussed later), which bind to Trk expressed on RGC, promoting their survival and neurite outgrowth.
AG1478 stimulates RGC and retinal glia to release neurotrophins
The involvement of RGC and retinal glia in the mediation of AG1478 off-target effects is implied by: (i) the up-regulation of neurotrophin in retinal cultures after exposure to AG1478; (ii) the suppression of RGC neuritogenesis after reducing glial numbers; (iii) reports that glia secrete multiple growth promoting factors (Garcia et al., 2002; Oku et al., 2002; de Melo Reis et al., 2008) including BDNF, CNTF, leukaemia inhibitory factor, bone morphogenetic protein, glial cell derived neurotrophic factor, fibroblast growth factor-2 and NT-3, NT-4/5 (Gomezpinilla et al., 1995; Dougherty et al., 2000; Harada et al., 2002; Chang et al., 2003; Wu et al., 2004; Agarwal et al., 2005 Agarwal et al., , 2007 Seki et al., 2005; Faijerson et al., 2006; Domeniconi et al., 2007; White and Jakeman, 2008) ; and (iv) retinal glia have the potential to act as intermediaries between exogenous stimuli and target RGC-for example, lens injury and vitreal inflammation stimulate retinal astrocyte/Mü ller cells to release CNTF, which may promote RGC survival and axon growth (Muller et al., 2007 (Muller et al., , 2009 Hauk et al., 2008) . Although CNTF is a key factor for survival and regeneration of RGC Muller et al., 2007) , and is up-regulated in activated Mü ller cells after ischaemia (Jo et al., 1999) and optic nerve crush (Sarup et al., 2004) , our MAb228 blockade results exclude CNTF as a mediator of AG1478-induced disinhibited RGC neurite outgrowth, whereas our immunohistochemical and K252a findings support the hypothesis that neurotrophins are released from retinal RGC/glia (Lorber et al., , 2009 ) in response to AG1478. We are currently investigating the mechanism by which EGFR inhibitors promote neurotrophin production and release and this will form the basis of future publications. Rises in intracellular Ca 2+ increase neurotrophin secretion (Blochl and Thoenen, 1995; Goodman et al., 1996) and neurotrophin/Trk interactions activate multiple signal transduction pathways, leading to increases in intracellular calcium concentration (Kaplan and Miller, 1997) , suggesting that neurotrophins might regulate auto-secretion. Stimulated release of NGF and BDNF by neurotrophins has been reported in hippocampal slices, primary neurons in culture and PC12 cells (Canossa et al., 1997) . Therefore, it is possible that one off-target mechanism of AG1478 is to initiate Ca 2+ release from intracellular stores, leading to increased neurotrophin production and secretion via a positive feedback loop (Kruttgen et al., 1998) .
AG1478 activates TACE and induces regulated intramembraneous proteolysis of p75 NTR
The observation that suppression of EGFR activation in vivo and in vitro promotes RGC axon/neurite regeneration (Koprivica et al., 2005) suggested that disinhibition alone was axogenic. However, priming the growth response of mature RGC, together with inactivation of growth inhibitory signalling molecules, are prerequisites for robust RGC axon regeneration (Fischer et al., 2004a, b) . RGC neurite growth disinhibition by AG1478-conditioned medium correlated with activation of TACE, regulated intramembraneous proteolysis of p75 NTR and reduced
RhoA activation, and is in accord with our previous reports of disinhibited RGC and DRGN neurite outgrowth in the presence of CME in vitro (Ahmed et al., 2005 (Ahmed et al., , 2006a Logan et al., 2006) and RGC axon regeneration in vivo (Logan et al., 2006) . Accordingly, we propose that the disinhibition of neurite/axon growth seen after AG1478/PD168393-treatment is not mediated through EGFR, but induced by high titres of neurotrophins released from RGC/retinal glia which initiate regulated intramembraneous proteolysis and drive growth cone advance. For example, ROCK blockade, using the specific inhibitor Y27632, promotes disinhibited adult RGC neurite outgrowth only in the presence of CNTF, an effect also potentiated by raised cAMP levels (Ahmed et al., 2009a) .
Neuritogenic effects of EGFR inhibition are recapitulated using a combination of neurotrophin and raised cAMP levels
In CME-inhibited adult retinal cultures, neurotrophins do not produce significant RGC neurite outgrowth. Similarly, isolated modulation of cAMP levels are also unable to effect significant neurite outgrowth. In contrast, treatment of CME-inhibited retinal cultures with combined neurotrophins and raised cAMP levels recapitulate the disinhibited growth seen after treatment with EGFR inhibitors. This suggests that our analyses have identified the key effectors of disinhibited growth, further supporting our previous observations that optimal neurite outgrowth is dependent on both sufficient neurotrophic drive and disinhibition (Ahmed et al., 2005 (Ahmed et al., , 2006a (Ahmed et al., , b, 2009a Logan et al., 2006) . Although the neural cell adhesion molecule plays a role in EGFRrelated inhibitory signalling (Povlsen et al., 2008) , signal transduction cascades activated by neural cell adhesion molecule act through fibroblast growth factor receptor activation (Niethammer et al., 2002) . In our models, neuritogenic activity is ablated through the use of Trk-Fc fusion proteins and kinase inhibitors such as k252a, which work independently of fibroblast growth factor receptor activation, suggesting that the EGFR signalling pathway is not relevant to their induction of off-target AG1478 effects.
Conclusions
In conclusion, our results confirm previous findings demonstrating that EGFR inhibitors, including AG1478 and PD168393, suppress pEGFR levels and stimulate disinhibited RGC neurite outgrowth. However, pEGFR is exclusively found in retinal and optic nerve glia but is absent from RGC and their axons, suggesting that these agents act off-target. In support of this conclusion, AG1478 stimulates the release of neurotrophins from RGC and retinal glia, and elevates cAMP levels. Neurotrophin and cAMP in combination provide the stimulus for mobilizing axogenic protein synthesis and also induce regulated intramembraneous proteolysis of p75 NTR and lower levels of pEGFR. These combined effects promote disinhibited RGC neurite growth in the presence of CME. Understanding the off-target nature of AG1478-mediated axogenesis is likely to identify novel therapeutic targets for promoting disinhibited CNS axon regeneration after CNS injury.
